Ameltolide

• CAT Number: I021948
• CAS Number: 787-93-9
• Molecular Formula: C15H16N2O
• Molecular Weight: 240.31
• Purity: 98%
• Synonyms: Ameltolide
• Solubility: Soluble in DMSO
• Appearance: Solid powder
• Storage: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
• IUPAC Name: 4-amino-N-(2,6-dimethylphenyl)benzamide
• InChI: InChI=1S/C15H16N2O/c1-10-4-3-5-11(2)14(10)17-15(18)12-6-8-13(16)9-7-12/h3-9H,16H2,1-2H3,(H,17,18)
• InChIKey: HZIWGOAXOBPQGY-UHFFFAOYSA-N
• SMILES: CC1=C(C(=CC=C1)C)NC(=O)C2=CC=C(C=C2)N

Ameltolide（Cat No.:I021948）is a selective adenosine A1 receptor agonist with potential applications in cardiovascular medicine. It works by stimulating the A1 receptor, which helps to reduce heart rate, decrease myocardial oxygen demand, and improve blood flow to the heart, making it a potential treatment for conditions like angina and heart failure. Ameltolide has been studied for its ability to improve cardiac function by modulating the effects of adenosine, a key signaling molecule in the regulation of heart rhythm and blood flow. Research is ongoing to evaluate its safety, efficacy, and therapeutic potential in clinical settings.

Reference

1: Iman M, Saadabadi A, Davood A, Shafaroodi H, Nikbakht A, Ansari A, Abedini M. Docking, Synthesis and Anticonvulsant Activity of N-substituted Isoindoline-1,3-dione. Iran J Pharm Res. 2017 Spring;16(2):586-595. PubMed PMID: 29721024; PubMed Central PMCID: PMC5603866.
2: Iman M, Saadabadi A, Davood A. Docking studies of phthalimide pharmacophore as a sodium channel blocker. Iran J Basic Med Sci. 2013 Sep;16(9):1016-21. PubMed PMID: 24171082; PubMed Central PMCID: PMC3804840.
3: Territo PR, Shannon HE, Newhall K, Barnhart SD, Peters SC, Engleking DR, Bin T, Burnett TJ, Rodewald JM, Abdul-Karim B, Freise KJ. Nonlinear mixed effects pharmacokinetic/pharmacodynamic analysis of the anticonvulsant ameltolide (LY201116) in a canine seizure model. J Vet Pharmacol Ther. 2008 Dec;31(6):562-70. doi: 10.1111/j.1365-2885.2008.00995.x. PubMed PMID: 19000280.
4: Yogeeswari P, Sriram D, Sahitya P, Ragavendran JV, Ranganadh V. Synthesis and anticonvulsant activity of 4-(2-(2,6-dimethylphenylamino)-2-oxoethylamino)-N-(substituted)butanamides: a pharmacophoric hybrid approach. Bioorg Med Chem Lett. 2007 Jul 1;17(13):3712-5. Epub 2007 Apr 13. PubMed PMID: 17481896.
5: Yogeeswari P, Sriram D, Thirumurugan R, Raghavendran JV, Sudhan K, Pavana RK, Stables J. Discovery of N-(2,6-dimethylphenyl)-substituted semicarbazones as anticonvulsants: hybrid pharmacophore-based design. J Med Chem. 2005 Oct 6;48(20):6202-11. PubMed PMID: 16190747.
6: Askwith CC, Wemmie JA, Price MP, Rokhlina T, Welsh MJ. Acid-sensing ion channel 2 (ASIC2) modulates ASIC1 H+-activated currents in hippocampal neurons. J Biol Chem. 2004 Apr 30;279(18):18296-305. Epub 2004 Feb 11. PubMed PMID: 14960591.
7: Bourhim M, Poupaert JH, Stables JP, Vallée L, Vamecq J. Design, anticonvulsive and neurotoxic properties of retrobenzamides. N-(Nitrophenyl)benzamides and N-(aminophenyl)benzamides. Arzneimittelforschung. 1999 Feb;49(2):81-7. PubMed PMID: 10083974.
8: Vamecq J, Lambert D, Poupaert JH, Masereel B, Stables JP. Anticonvulsant activity and interactions with neuronal voltage-dependent sodium channel of analogues of ameltolide. J Med Chem. 1998 Aug 27;41(18):3307-13. PubMed PMID: 9719582.
9: Kanyonyo MR, Poupaert JH, Lambert DM. Anticonvulsant profile of 4-amino-(2-methyl-4-aminophenyl)benzamide in mice and rats. Pharmacol Toxicol. 1998 Jan;82(1):47-50. PubMed PMID: 9527647.
10: Bourhim M, Kanyonyo MD, Lambert DM, Poupaert JH, Stables JP, Vamecq J. [Rational conception, synthesis and evaluation of phenytoinergic potential anticonvulsants. A series ofretrobenzamides: N-(nitrophenyl) benzamides and N-(aminophenyl) benzamides]. J Pharm Belg. 1997 Sep-Oct;52(5):181-9. French. PubMed PMID: 9432526.
11: Van Derpoorten K, Balzarini J, De Clercq E, Poupaert JH. Anti-HIV activity of N-1-adamantyl-4-aminophthalimide. Biomed Pharmacother. 1997;51(10):464-8. PubMed PMID: 9863507.
12: Diouf O, Bourhim M, Lambert DM, Poupaert JH, Stables JP, Vamecq J. Anticonvulsant and neurotoxicological properties of 4-amino-N-(2-ethylphenyl)benzamide, a potent ameltolide analogue. Biomed Pharmacother. 1997;51(3):131-6. PubMed PMID: 9181049.
13: Engelhardt JA, Parli CJ, Kovach PM, Shoufler JR, Emmerson JL, Leander JD. Subchronic toxicity, metabolism, and pharmacokinetics of the aminobenzamide anticonvulsant ameltolide (LY201116) in rhesus monkeys. Fundam Appl Toxicol. 1992 Aug;19(2):197-201. PubMed PMID: 1516775.
14: Leander JD. Interaction of the anticonvulsant ameltolide with standard anticonvulsants. Epilepsia. 1992 Jul-Aug;33(4):705-11. PubMed PMID: 1628588.
15: Leander JD, Parli CJ, Potts B, Lodge D. Relation of plasma and brain concentrations of the anticonvulsant ameltolide to its pharmacologic effects. Epilepsia. 1992 Jul-Aug;33(4):696-704. PubMed PMID: 1628587.
16: Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia. 1992 May-Jun;33(3):573-6. PubMed PMID: 1534297.
17: Pohland RC, Vavrek MT. Ameltolide. II: Placental transfer of radiocarbon following the oral administration of a novel anticonvulsant in rats. Teratology. 1991 Jul;44(1):45-9. PubMed PMID: 1957262.
18: Higdon GL, McKinley ER, Markham JK. Ameltolide. I: Developmental toxicology studies of a novel anticonvulsant. Teratology. 1991 Jul;44(1):37-44. PubMed PMID: 1957261.
19: Robertson DW, Beedle EE, Krushinski JH, Lawson RR, Parli CJ, Potts B, Leander JD. Synthesis and pharmacological evaluation of a major metabolite of ameltolide, a potent anticonvulsant. J Med Chem. 1991 Apr;34(4):1253-7. PubMed PMID: 2016702.
20: Stark LG, Albertson TE. The effects of LY-201116 [4-amino-N-(2,6-dimethylphenyl) benzamide] on the amygdala-kindled rat. Neuropharmacology. 1990 Nov;29(11):1085-9. PubMed PMID: 2087258.